[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"SMED Clinical Research\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":43},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":4,"eligibilityCriteria":13,"healthyVolunteers":10,"sex":14,"minAge":15,"maxAge":4,"enrollmentInfo":16,"targetDuration":4,"studyType":19,"phases":20,"briefSummary":22,"conditions":23,"keywords":25,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100615952",false,"NCT07299292","Castration With Abiraterone 250 mg Without LHRH Analogs or Blockers in Patients With Prostate Cancer Requiring Hormonal Intensification (Multicenter Phase 2)","Inclusion Criteria:\n\n* Age ≥18 years.\n* Histologically confirmed prostate adenocarcinoma.\n* Treated at Hospital Durand (Argentina) or Instituto Oncológico del Oriente Boliviano (Bolivia).\n* Indicated for hormonal intensification (high\u002Fvery high risk candidates for RT, or mHSPC for doublet\u002Ftriplet).\n* No prior ADT.\n* ECOG 0-2; adequate hepatic\u002Frenal function; K+ ≥3.5 mmol\u002FL; controlled BP.\n\nExclusion Criteria:\n\n* Hypersensitivity to ABI\u002Fprednisone; moderate-severe hepatic impairment; uncontrolled hypertension; refractory hypokalemia.\n* Concurrent therapy with strongly contraindicated\u002Finducing drugs affecting ABI levels without possibility of adjustment.","MALE","18 Years",{"count":17,"type":18},60,"ESTIMATED","INTERVENTIONAL",[21],"PHASE2","Hypothesis\n\nThe use of Abiraterone 250 mg with food + prednisone, without LHRH analogs or blockers (ADT), achieves castration-level testosterone at 30 days in ≥80-90% of cases.",[24],"Prostate Cancer (Diagnosis)",[26,27,28,29],"prostate cancer","castration","abiraterone","hormonal intensification","RECRUITING","2025-12-09",{"date":33,"type":34},"2025-12-23","ACTUAL",{"date":36,"type":34},"2025-12-01",{"date":38,"type":18},"2027-03-30",{"name":40,"class":41},"SMED Clinical Research","OTHER",3,""]